Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05052801 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

547

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Bemarituzumab
DRUG: mFOLFOX6
DRUG: Placebo

Sponsor

Amgen

Collaborators

[object Object]